Drug Profile
Research programme: 11-beta hydroxysteroid dehydrogenase inhibitors - Johnson & Johnson
Alternative Names: JNJ 25918646Latest Information Update: 11 Sep 2008
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Adamantanes
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity